A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Initial diagnosis of nAMD within 9 months prior to the screening visit
Previous treatment with at least three anti-vascular endothelial growth factor (VEGF) IVT injections for nAMD per standard-of-care (SOC) within 6 months prior to the screening visit
Demonstrated response to prior anti-VEGF IVT treatment since diagnosis
Availability of historical VA data prior to the first anti-VEGF treatment for nAMD up to the screening visit
BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent), using Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters
All subtypes of nAMD lesions are permissible
Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), indocyanine green angiography (ICGA), fundus autofluorescence (FAF), and optical coherence tomography (OCT) images
You may not be if
A. Prior Ocular Treatment Study Eye
History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD
Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy
Previous treatment with corticosteroid IVT injection or corticosteroid implants
Previous intraocular device implantation (not including intraocular lens implants)
Previous laser (any type) used for age-related macular degeneration (AMD) treatment
Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit
Prior treatment with IVT treatments for geographic atrophy
Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant
Either Eye
Prior treatment with brolucizumab
Prior gene therapy for nAMD or other ocular diseases
Previous participation in any ocular disease studies of investigational drugs and/or devices, within 3 months or five elimination half-lives of the investigational therapy, whichever is longer, preceding the screening visit
B. Choroidal Neovascularization (CNV) Lesion Characteristics
Study Eye
Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 millimeter square \[mm\^2\]) in size at screening
Subfoveal fibrosis or subfoveal atrophy
Either Eye • CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia
C. Concurrent Ocular Conditions Study Eye
Retinal pigment epithelial tear
Any concurrent intraocular condition
Active intraocular inflammation (grade trace or above)
History of vitreous hemorrhage
History of rhegmatogenous retinal detachment
History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the randomization visit
History of pars plana vitrectomy surgery
Aphakia or absence of the posterior capsule
Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia
Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery
Intraocular surgery (including cataract surgery) within 3 months preceding the randomization visit
Uncontrolled ocular hypertension or glaucoma
History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
History of corneal transplant
Fellow (Non-Study) Eye
Non-functioning fellow eye
Either Eye
Any history of uveitis
Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis